210 related articles for article (PubMed ID: 11364399)
1. FDA explores new antiretroviral trial designs: interview with David Feigal, M.D. Interview by John S. James.
Feigal D
AIDS Treat News; 1997 Jun; (No 273):1-5. PubMed ID: 11364399
[TBL] [Abstract][Full Text] [Related]
2. Protease inhibitors and beyond: interview with David Feigal, M.D. Interview by John S James.
Feigal D
AIDS Treat News; 1995 Mar; (no 219):1-6. PubMed ID: 11362331
[TBL] [Abstract][Full Text] [Related]
3. FDA community meeting May 16: clinical trials and viral load. Food and Drug Administration.
AIDS Treat News; 1997 May; (No 270):3. PubMed ID: 11364324
[TBL] [Abstract][Full Text] [Related]
4. The role of resistance testing in clinical trial design and product labelling: a regulatory perspective.
Laessig KA; Murray JS; Chikami G
Antivir Ther; 2000 Mar; 5(1):77-83. PubMed ID: 10846597
[TBL] [Abstract][Full Text] [Related]
5. FDA reform in Congress: interview with Peter Barton Hutt. Food and Drug Administration. Interview by John S. James.
Hutt PB
AIDS Treat News; 1996 Apr; (no 245):4-5. PubMed ID: 11363623
[TBL] [Abstract][Full Text] [Related]
6. HE2000 begins clinical trials: interview with James Frincke, Ph.D. Interview by John S. James.
Frincke J
AIDS Treat News; 1999 Jun; (No 320):4-7. PubMed ID: 11366467
[TBL] [Abstract][Full Text] [Related]
7. Lessons learned from independent central review.
Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
[TBL] [Abstract][Full Text] [Related]
8. FDA workshop on clinical trial design, September 6-7--registration by Aug. 18. Food and Drug Administration.
James JS
AIDS Treat News; 1995 Aug; (no 228):5-6. PubMed ID: 11362627
[TBL] [Abstract][Full Text] [Related]
9. Adefovir: FDA committee votes against approval. Food and Drug Administration.
James JS
AIDS Treat News; 1999 Nov; (No 330):1-2. PubMed ID: 11367170
[TBL] [Abstract][Full Text] [Related]
10. Abacavir's trials and tribulations.
Gilden D
GMHC Treat Issues; 1998 Nov; 12(11):1-3. PubMed ID: 11365905
[TBL] [Abstract][Full Text] [Related]
11. Clinical trials and viral load: statement for FDA community meeting May 16. Food and Drug Administration.
James JS
AIDS Treat News; 1997 May; (No 271):1-4. PubMed ID: 11364367
[TBL] [Abstract][Full Text] [Related]
12. FDA notifications. FDA postpones CCR5 Antagonist Review Group meeting.
AIDS Alert; 2006 Jan; 21(1):11-2. PubMed ID: 16470945
[No Abstract] [Full Text] [Related]
13. Update on new antiretroviral drugs. An interview with Harold Kessler, M.D. by Matt Sharp.
Kessler H
Posit Aware; 2007; 18(6):22-4. PubMed ID: 18074429
[No Abstract] [Full Text] [Related]
14. HIV research overview: interview with David Ho, M.D. Interview by John S. James.
Ho D
AIDS Treat News; 1997 Nov; (No 282):1-6. PubMed ID: 11364903
[TBL] [Abstract][Full Text] [Related]
15. FDA evaluates accelerated approval process. Food and Drug Administration.
Common Factor; 1995 Apr; (no 10):18. PubMed ID: 11362343
[TBL] [Abstract][Full Text] [Related]
16. Is it time to rethink the expanded-access programs for HIV infection?
Amorosa V; Tebas P
J Infect Dis; 2007 Oct; 196(7):974-7. PubMed ID: 17763316
[TBL] [Abstract][Full Text] [Related]
17. Abacavir (Ziagen) approval recommended.
AIDS Treat News; 1998 Nov; (No 306):4. PubMed ID: 11365961
[TBL] [Abstract][Full Text] [Related]
18. Testimony on accelerated approval.
Hogan C
GMHC Treat Issues; 2003 Nov; 17(11):12. PubMed ID: 14717108
[TBL] [Abstract][Full Text] [Related]
19. Adefovir rejected.
Res Initiat Treat Action; 1999 Dec; 5(5):23. PubMed ID: 11366890
[TBL] [Abstract][Full Text] [Related]
20. FDA clarifies rules, allows combining antiretrovirals in clinical trials. Food and Drug Administration.
AIDS Treat News; 1999 Nov; (No 331):5-6. PubMed ID: 11367127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
